focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Regulatory News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,166.00
Bid: 12,132.00
Ask: 12,136.00
Change: -6.00 (-0.05%)
Spread: 4.00 (0.033%)
Open: 12,180.00
High: 12,198.00
Low: 12,076.00
Prev. Close: 12,172.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

15 Dec 2021 15:00

RNS Number : 7755V
AstraZeneca PLC
15 December 2021
 

15 December 2021 15:00 GMT

 

Transaction by Person Discharging Managerial Responsibilities

 

AstraZeneca PLC (the Company) announces that Tony Mok, a Non-Executive Director of the Company, purchased 2,000 of the Company's American Depositary Shares (ADSs) on 13 December 2021. Two ADSs are equivalent to one Ordinary Share of $0.25 in the Company.

 

Further details are set out in the attached notification, made in accordance with the requirements of the EU Market Abuse Regulation (since it forms part of UK law pursuant to the European Union (Withdrawal) Act 2018).

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

a)

 

Name

Tony Mok

2

 

Reason for the notification

 

a)

 

Position/status

 

Non-Executive Director

b)

 

Initial notification /Amendment

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

 

Name

AstraZeneca PLC

b)

 

LEI

PY6ZZQWO2IZFZC3IOL08

4i

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

 

Identification code

AstraZeneca PLC American Depositary Shares

 

 

CUSIP: 046353108

b)

 

Nature of the transaction

 

 

Purchase of AstraZeneca PLC American Depositary Shares

c)

 

Price(s) and volume(s)

 

 

Price(s)

Volume(s)

US$54.29

2,000

d)

 

Aggregated information

 

- Aggregated volume

- Price

Not applicable - single transaction

 

 

 

 

e)

 

Date of the transaction

 

13 December 2021

f)

 

Place of the transaction

 

XNAS

 

 

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.

 

Contacts

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

 

 

Adrian KempCompany Secretary

AstraZeneca PLC

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHUVOORAOUUAAA
Date   Source Headline
14th Sep 20187:00 amRNSFDA approves AZ's Lumoxiti in hairy cell leukaemia
7th Sep 20187:00 amRNSTezepelumab FDA Breakthrough Therapy Designation
6th Sep 20187:00 amRNSDirectorate Change
3rd Sep 20183:00 pmRNSTotal Voting Rights
31st Aug 20187:00 amRNSAstraZeneca Update on Anifrolumab in SLE
30th Aug 20187:00 amRNSEC approves Bydureon BCise device for T2 diabetes
23rd Aug 20187:00 amRNSAstraZeneca PIIIb trial update for Bevespi in COPD
21st Aug 20187:00 amRNSAZ's Tagrisso approved in Japan for 1st-line NSCLC
15th Aug 20187:00 amRNSAstraZeneca prices a $3bn bond issue
3rd Aug 20187:00 amRNSEMA grants OD for selumetinib in NF1
1st Aug 20183:00 pmRNSTotal Voting Rights
27th Jul 20182:00 pmRNSCHMP recommends Imfinzi for Stage III nsclc
26th Jul 20187:00 amRNSAZN: H1 2018 Results
24th Jul 20187:00 amRNSAtacand to be divested to Cheplapharm in Europe
18th Jul 20184:11 pmRNSHolding(s) in Company
18th Jul 201812:00 pmRNSHolding(s) in Company
2nd Jul 20183:00 pmRNSTotal Voting Rights
2nd Jul 20187:00 amRNSImfinzi approved in Japan for Stage III nsclc
2nd Jul 20187:00 amRNSLynparza approved in Japan for BRCAm breast cancer
29th Jun 20183:00 pmRNSBydureon receives positive CHMP opinion for BCise
28th Jun 20181:30 pmRNSAZ and Luye Pharma complete agreement for Seroquel
27th Jun 20187:00 amRNSLynparza: significant PFS 1st-line ovarian cancer
26th Jun 20187:00 amRNSBoard Committee Changes
22nd Jun 20187:00 amRNSPublication of a Prospectus
12th Jun 20187:00 amRNSUpdate: lanabecestat Phase III Alzheimer's trials
8th Jun 20185:30 pmRNSEU APPROVES TAGRISSO FOR 1ST-LINE NSCLC
8th Jun 20187:00 amRNSDirector Declaration
1st Jun 20183:00 pmRNSBlock listing Interim Review
1st Jun 20183:00 pmRNSTotal Voting Rights
1st Jun 201811:00 amRNSDirector Declaration
30th May 20187:00 amRNSUpdate on TERRANOVA PIII trial for Fasenra in COPD
25th May 20187:00 amRNSAZ's Imfinzi: significant OS in Stage III nsclc
21st May 20187:00 amRNSAZ regulatory submission in Japan for Forxiga
21st May 20187:00 amRNSUS FDA approves Lokelma for adult hyperkalaemia
18th May 20185:30 pmRNSResult of AGM
18th May 20187:00 amRNSAZN: Q1 2018 Results
11th May 20187:00 amRNSAstraZeneca update on Fasenra PIII trial in COPD
8th May 201811:00 amRNSEMA approves Lynparza: maintenance ovarian cancer
8th May 20187:00 amRNSAZ and Luye Pharma enter agreement for Seroquel
4th May 201812:00 pmRNSDirector Declaration
1st May 20183:00 pmRNSTotal Voting Rights
27th Apr 201812:30 pmRNSAZ: positive CHMP for Tagrisso first-line nsclc
24th Apr 20187:00 amRNSAstraZeneca:high level results of the ARCTIC trial
24th Apr 20187:00 amRNSIssue of Equity - AstraZeneca
19th Apr 20187:00 amRNSFDA approves Tagrisso for 1st-line use in NSCLC
13th Apr 201811:00 amRNSNotice of AGM
5th Apr 20187:00 amRNSDirectorate Change
3rd Apr 20183:00 pmRNSTotal Voting Rights
3rd Apr 20187:00 amRNSFDA TO REVIEW MOXETUMOMAB FOR HAIRY CELL LEUKAEMIA
3rd Apr 20187:00 amRNSAZ AND MSD SUBMIT LYNPARZA FOR BREAST CANCER IN EU

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.